AstraZeneca PLC (AZN)vsENvue Medical Inc. (FEED)
AZN
AstraZeneca PLC
$156.45
+0.28%
HEALTHCARE · Cap: $243.86B
FEED
ENvue Medical Inc.
$0.44
+14.70%
HEALTHCARE · Cap: $3.72M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2813564% more annual revenue ($61.37B vs $2.18M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 65/100 (B-).
AZN
Strong Buy65
out of 100
Grade: B-
FEED
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.4%
Fair Value
$196.68
Current Price
$156.45
$40.23 discount
Intrinsic value data unavailable for FEED.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : FEED
The strongest argument for FEED centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : FEED
The primary concerns for FEED are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while FEED is a value play — different risk/reward profiles.
FEED carries more volatility with a beta of 1.35 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (65/100 vs 30/100), backed by strong 17.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
ENvue Medical Inc.
HEALTHCARE · MEDICAL DEVICES · USA
ENvue Medical Inc. (FEED) is a pioneering healthcare technology company that specializes in the development of cutting-edge medical devices and integrated software solutions aimed at enhancing patient care management. By leveraging innovation to optimize health outcomes and streamline recovery processes, ENvue is well-positioned to capitalize on substantial growth opportunities within the dynamic healthcare landscape. With a strong product pipeline and strategic collaborations, the company represents a compelling investment for institutional investors interested in the future of medical devices and digital health advancements.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?